source
- Swiss biotech Windward Bio raises $165 million to launch Phase 3 asthma trial for China-derived drugSwiss biotech Windward Bio announced it has secured $165 million in financing. The capital will be used to move one of its two experimental medicines, originally discovered in China, into a Phase…
- Vertex halts mRNA cystic fibrosis program citing tolerability concernsVertex Pharmaceuticals announced it is ending development of its mRNA-based cystic fibrosis therapy after encountering tolerability problems that echo challenges seen elsewhere in the field. The B…